Androlabs Calls for Earlier Action on Erectile Dysfunction as Cardiovascular Warning Sign

Androlabs is calling for a shift in how erectile dysfunction is understood, arguing that ED should be treated as a clinically meaningful warning sign rather than an isolated or age-related problem.

The company points to evidence linking erectile dysfunction with broader health risks, particularly cardiovascular disease. According to data cited by Androlabs, more than half of men aged 40 to 70 in the United States experience some degree of ED. Prevalence is estimated to rise by around 10% with each decade of life.

Androlabs says erectile function is closely tied to blood flow and endothelial health, meaning ED can appear before other symptoms of cardiovascular disease. New clinical evidence published in April 2026 suggests heart disease may develop two to five years after the onset of erectile dysfunction, creating a window for earlier investigation and intervention.

Professor Albert Ferro, Professor of Cardiovascular Clinical Pharmacology at King’s College London, said atherosclerosis can affect the arteries supplying the penis and may indicate similar issues elsewhere in the body.

The company argues that stigma, embarrassment, and poor engagement with healthcare continue to delay diagnosis and treatment. CEO and co-founder Charlie Bryant said men are still waiting too long to act on early signs, increasing the risk that more serious conditions go undetected.

Androlabs is urging men experiencing ED symptoms to speak to a GP or qualified healthcare professional, while calling for healthcare systems to normalise conversations around sensitive symptoms and encourage earlier action.